FindTrial
Sign In

Comparison of the effect of Cabergoline versus Dienogest on markers in endometriosis

Comparison of the effect of Cabergoline versus Dienogest on serum pro inflammatory markers in endometriosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051886
Enrollment
60
Registered
2023-04-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N801- Endometriosis of ovary

Interventions

Intervention1: Cabergoline: 0.5mg twice weekly for 6 months Control Intervention1: Dienogest: 2mg OD for 6 months

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women with diagnosis of endometriosis on laparoscopy or ultrasound.

Exclusion criteria

Exclusion criteria: 1.Women who want to conceive immediately. 2.Body mass index of (BMI) more than 30 kg/m2 3.Chronic inflammatory disorders 4.History of recent infection and inflammatory conditions (3months) 5.Patients with known history of allergy to one of the study drug

Design outcomes

Primary

MeasureTime frame
Change in the serum levels of pro inflammatory levels post treatment 1.Serum Vascular endothelial growth factor level 2.Serum Tumor necrosis factor alpha level 3.Serum high sensitivity C Reactive protein Timepoint: 0,6,9 months—

Secondary

MeasureTime frame
To compare the efficacy of cabergoline with dienogest on 1.Reduction in post treatment pain by VAS 2.Reduction in post treatment volume measured on USG 3.Pain scoring by VAS after 3 months of stopping drug Timepoint: 0,3,6,9 months—

Countries

India

Contacts

Public ContactDr Ritu Kushwah

AIIMS New Delhi

garimakhadgawat@gmail.com9868246702

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026